A Multicenter Longitudinal Study to Evaluate the Correlation Between Oculometric Measures and Clinical Assessment in Patients With Idiopathic Parkinson's Disease (PALOMA Trial)

Status: Recruiting
Location: See all (5) locations...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This is a multicenter longitudinal study in about 300 patients with Idiopathic Parkinson's disease, who will be evaluated in several clinical centers with a clinical assessment and an oculometric examination during a time period with specific intervals. This study aims to evaluate the correlation between oculometric measures and clinical assessment over time, as well as the potential to detect early change in clinical status using an oculometric assessment.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 40
Maximum Age: 85
Healthy Volunteers: f
View:

• Men and women with idiopathic PD (Hoehn \& Yahr scale 1-2)

• Age between 40 and 85 years old

• 0 to 5 years' time since diagnosis

• Normal or corrected vision

• Ability to follow instructions

• Willing and able to sign an informed consent form

• No anticipated changes in PD medications from baseline throughout the study duration based on clinical status during screening

• If treated, stable on treatment for at least 3 months

Locations
United States
Illinois
Rush University
RECRUITING
Chicago
Other Locations
Portugal
AIBILI research center
RECRUITING
Coimbra
Spain
Instituto de Biomedicina de Sevilla (IBiS)
RECRUITING
Seville
Switzerland
University Hospital Zürich
NOT_YET_RECRUITING
Zurich
United Kingdom
The VCTC
RECRUITING
Oxford
Contact Information
Primary
Eitan Raveh, PhD
eitan@neuralight.ai
00972586277944
Time Frame
Start Date: 2023-08-21
Estimated Completion Date: 2025-11-15
Participants
Target number of participants: 300
Treatments
Experimental: PD patients
Men and women with idiopathic PD (Hoehn \& Yahr scale 1-2) aged 40-85 years
Related Therapeutic Areas
Sponsors
Collaborators: European Clinical Research Infrastructure Network
Leads: NeuraLight

This content was sourced from clinicaltrials.gov